Advances in Therapeutic Strategies for Prostate Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 1 July 2025 | Viewed by 1554

Special Issue Editors


E-Mail Website
Guest Editor
Department of Urology, San Giuseppe Hospital, Multimedica Group, Milan, Italy
Interests: cancer

E-Mail Website
Guest Editor
Department of Urology, San Giuseppe Hospital, Multimedica Group, 20123 Milano, Italy
Interests: robotic and laparoscopic surgery; urinary calculus; oncological urology; andrology; incontinence and genitourinary prolapse; phimosis and circumcision
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Advances in therapeutic strategies for prostate cancer have seen significant progress in recent years. These advancements encompass various approaches, including:

  1. Precision Medicine: Tailoring treatments based on the patient's genetic profile has become increasingly common. This allows for more targeted therapies and reduced side effects.
  1. Immunotherapy: Immune checkpoint inhibitors and other immunotherapeutic approaches have shown promise in boosting the body's immune response to prostate cancer cells.
  1. Radiation Therapy: Techniques such as stereotactic body radiation therapy (SBRT) and proton therapy offer more precise and effective ways to target prostate tumors while minimizing damage to surrounding tissues.
  1. Hormone Therapy: New drugs and combinations have been developed to improve the management of advanced prostate cancer by blocking or inhibiting the hormones that fuel tumor growth.
  1. Minimally Invasive Surgery: Robotic-assisted surgery has enhanced the precision and recovery time for patients undergoing prostatectomies.
  1. Liquid Biopsies: Liquid biopsy techniques have emerged to detect prostate cancer at an earlier stage and monitor its progression more effectively.
  1. Targeted Therapies: Drugs that specifically target key molecular pathways involved in prostate cancer growth have been developed, offering new treatment options.

These advances collectively represent a more personalized and effective approach to prostate cancer treatment, providing hope for improved outcomes and quality of life for patients. Ongoing research and clinical trials continue to drive innovation in this field.

Dr. Angelo Naselli
Dr. Giacomo Maria Pirola
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • radiation therapy
  • hormone therapy
  • targeted therapies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

18 pages, 1033 KiB  
Systematic Review
Prostate Tissue Microbiome in Patients with Prostate Cancer: A Systematic Review
by Daniela F. Ward Grados, Onuralp Ergun, Carly D. Miller, Petr Gaburak, Nana A. Frimpong, Oluwatobi Shittu and Christopher A. Warlick
Cancers 2024, 16(8), 1549; https://doi.org/10.3390/cancers16081549 - 18 Apr 2024
Cited by 1 | Viewed by 1227
Abstract
Some researchers have speculated that the prostatic microbiome is involved in the development of prostate cancer (PCa) but there is no consensus on certain microbiota in the prostatic tissue of PCa vs. healthy controls. This systematic review aims to investigate and compare the [...] Read more.
Some researchers have speculated that the prostatic microbiome is involved in the development of prostate cancer (PCa) but there is no consensus on certain microbiota in the prostatic tissue of PCa vs. healthy controls. This systematic review aims to investigate and compare the microbiome of PCa and healthy tissue to determine the microbial association with the pathogenesis of PCa. We searched MEDLINE, Embase, and Scopus databases. Articles were screened by two independent and blinded reviewers. Literature that compared the prostatic tissue microbiome of patients with PCa with benign controls was included. We found that PCa may be associated with increased Propionibacterium acnes, the herpesviridae and papillomaviridae families, and Mycoplasma genitalium, but definitive conclusions cannot be drawn from the existing data. Challenges include the difficulty of obtaining uncontaminated tissue samples and securing tissue from healthy controls. As a result, methods are varied with many studies using cancerous and “healthy” tissue from the same prostate. The organisms chosen for each study were also highly variable, making it difficult to compare studies. These issues have led to lower confidence in our results. Overall, further work is warranted to better understand the implications of the prostatic microbiome in the pathogenesis of PCa. Full article
(This article belongs to the Special Issue Advances in Therapeutic Strategies for Prostate Cancer)
Show Figures

Figure 1

Back to TopTop